ATE439139T1 - Bakteriophage zur behandlung von bakteriellen biofilmen - Google Patents

Bakteriophage zur behandlung von bakteriellen biofilmen

Info

Publication number
ATE439139T1
ATE439139T1 AT04701383T AT04701383T ATE439139T1 AT E439139 T1 ATE439139 T1 AT E439139T1 AT 04701383 T AT04701383 T AT 04701383T AT 04701383 T AT04701383 T AT 04701383T AT E439139 T1 ATE439139 T1 AT E439139T1
Authority
AT
Austria
Prior art keywords
bacteriophage
biofilm
treatment
bacterial biofilm
bacteriophages
Prior art date
Application number
AT04701383T
Other languages
English (en)
Inventor
Richard Sharp
Gavin Hughes
A Hart
James Taggart Walker
Original Assignee
Health Prot Agency
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Prot Agency filed Critical Health Prot Agency
Application granted granted Critical
Publication of ATE439139T1 publication Critical patent/ATE439139T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/02—Carbon-oxygen lyases (4.2) acting on polysaccharides (4.2.2)
    • C12Y402/02003—Poly(beta-D-mannuronate) lyase (4.2.2.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2795/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT04701383T 2003-01-10 2004-01-12 Bakteriophage zur behandlung von bakteriellen biofilmen ATE439139T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0300597.2A GB0300597D0 (en) 2003-01-10 2003-01-10 Phage biofilms
PCT/GB2004/000073 WO2004062677A1 (en) 2003-01-10 2004-01-12 Bacteriophage for the treatment of bacterial biofilms

Publications (1)

Publication Number Publication Date
ATE439139T1 true ATE439139T1 (de) 2009-08-15

Family

ID=9950965

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04701383T ATE439139T1 (de) 2003-01-10 2004-01-12 Bakteriophage zur behandlung von bakteriellen biofilmen

Country Status (6)

Country Link
US (1) US7758856B2 (de)
EP (1) EP1587520B1 (de)
AT (1) ATE439139T1 (de)
DE (1) DE602004022506D1 (de)
GB (1) GB0300597D0 (de)
WO (1) WO2004062677A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1663265B1 (de) 2003-07-23 2015-09-23 Biocontrol Limited Bakteriophagen-enthaltende medikamente
US20060030539A1 (en) * 2004-08-06 2006-02-09 National Jewish Medical And Research Center Product and process for inhibition of biofilm development
WO2006137847A2 (en) * 2004-09-13 2006-12-28 Trustees Of Boston University Engineered enzymatically active bacteriophages and methods of uses thereof
WO2006095345A2 (en) 2005-03-08 2006-09-14 Ramot At Tel-Aviv University Ltd. Targeted drug-carrying bacteriophages
US7932029B1 (en) * 2006-01-04 2011-04-26 Si Lok Methods for nucleic acid mapping and identification of fine-structural-variations in nucleic acids and utilities
EP2004800B1 (de) 2006-04-04 2014-01-15 Henry Morris Krisch Verfahren zur herstellung von bakteriophagenzusammensetzungen sowie verfahren auf dem gebiet der phagentherapie
KR100781669B1 (ko) 2006-06-20 2007-12-03 주식회사 인트론바이오테크놀로지 황색포도상구균 특이적 사멸능을 갖는 박테리오파지
KR100759988B1 (ko) 2006-08-04 2007-09-19 주식회사 인트론바이오테크놀로지 황색포도상구균에 특이적인 항균 단백질
GB0704553D0 (en) * 2007-03-09 2007-04-18 Harper David R Beneficial effects of bacteriophage treatments
US7622293B2 (en) * 2007-06-18 2009-11-24 Intralytix, Inc. Pseudomonas aeruginosa: bacteriophage and uses thereof
US8734718B2 (en) 2007-08-17 2014-05-27 The Invention Science Fund I, Llc Systems, devices, and methods including catheters having an actively controllable therapeutic agent delivery component
US8366652B2 (en) * 2007-08-17 2013-02-05 The Invention Science Fund I, Llc Systems, devices, and methods including infection-fighting and monitoring shunts
KR100910961B1 (ko) 2007-09-13 2009-08-05 주식회사 인트론바이오테크놀로지 황색포도상구균의 균막 처치에 효과적인 박테리오파지 또는그것 유래의 용균단백질
DK2268142T3 (en) * 2007-11-27 2017-05-22 Algipharma As USING ALGINATED OLIGOMERS TO FIGHT BIOFILM
US8153119B2 (en) * 2007-12-18 2012-04-10 Trustees Of Boston University Engineered enzymatically active bacteriophage and methods for dispersing biofilms
WO2009137136A2 (en) 2008-02-15 2009-11-12 Trustees Of Boston University In vivo gene sensors
CA2744909A1 (en) * 2008-11-28 2010-06-03 Warren H. Finlay Bacteriophage compositions for treatment of bacterial infections
US20110208026A1 (en) * 2008-12-04 2011-08-25 Goodall Eleanor V Systems, devices, and methods including implantable devices with anti-microbial properties
US20110208021A1 (en) * 2008-12-04 2011-08-25 Goodall Eleanor V Systems, devices, and methods including implantable devices with anti-microbial properties
US9474831B2 (en) 2008-12-04 2016-10-25 Gearbox, Llc Systems, devices, and methods including implantable devices with anti-microbial properties
WO2010065135A1 (en) 2008-12-04 2010-06-10 Searete, Llc System, devices, and methods including actively-controllable sterilizing excitation delivery implants
US20110160681A1 (en) * 2008-12-04 2011-06-30 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems, devices, and methods including catheters having light removable coatings based on a sensed condition
US8043613B2 (en) 2009-02-12 2011-10-25 Intron Biotechnology, Inc. Podoviriedae bacteriophage having killing activity specific to Staphylococcus aureus
US8377866B2 (en) 2009-02-12 2013-02-19 Intron Biotechnology, Inc. Antimicrobial protein derived from Podoviridae bacteriophage specific to Staphylococcus aureus
WO2010141135A2 (en) 2009-03-05 2010-12-09 Trustees Of Boston University Bacteriophages expressing antimicrobial peptides and uses thereof
SI2437783T1 (sl) 2009-06-03 2014-04-30 Algipharma As Obdelava bakterije acinetobacter z alginatnimi oligomeri in antibiotiki
CA3004707C (en) 2009-09-02 2022-05-31 Synedgen Inc. Methods and compositions for disrupting biofilm utilizing chitosan-derivative compounds
RU2725726C2 (ru) * 2010-09-17 2020-07-03 Текнифар-Индустриа Текника Фармасьютика, С.А. Бактериофаги, фаговые пептиды и способы их применения
EP2465926A1 (de) * 2010-12-20 2012-06-20 University College Cork Pseudomonas aeruginosa-Bakteriophage und Verwendungen davon
CA2840749A1 (en) * 2011-07-01 2013-01-10 Synedgen, Inc. Methods and compositions of reducing and preventing bacterial growth and the formation of biofilm on a surface utilizing chitosan-derivative compounds
US12083158B2 (en) 2011-10-07 2024-09-10 Morehouse School Of Medicine Antibacterial compositions, methods of making and use thereof
US8669226B2 (en) 2011-10-07 2014-03-11 Morehouse School Of Medicine Antimicrobial compositions and methods of use thereof
US9546361B2 (en) 2012-10-12 2017-01-17 Lehigh University Thermally stable enzymes, compositions thereof and methods of using same
DE102013106455A1 (de) 2013-06-20 2014-12-24 Airbus Defence and Space GmbH Verfahren zur Dekontamination von bakteriologischen Verunreinigungen
EP3152303B1 (de) 2014-06-06 2021-11-24 The Hospital For Sick Children Lösliche bakterien- und pilzproteine sowie verfahren und verwendungen davon zum hemmen und dispergieren von biofilmen
JP2017526714A (ja) 2014-09-11 2017-09-14 シネジェン， インコーポレイテッド 組成物およびその使用方法
US11185555B2 (en) 2016-04-11 2021-11-30 Noah James Harrison Method to kill pathogenic microbes in a patient
WO2017211737A1 (fr) 2016-06-08 2017-12-14 Onelife S.A. Composition comprenant au moins une enzyme et au moins une molécule microbicide pour la prévention ou le traitement des infections post-implantatoires
WO2019231848A1 (en) 2018-05-30 2019-12-05 Morehouse School Of Medicine Antibacterial compositions, methods of making and use thereof
WO2020264096A1 (en) 2019-06-27 2020-12-30 Baylor College Of Medicine Systems and methods for generating bacteriophages adapted to infect a target bacterial strain
EP4142740A4 (de) 2020-04-30 2024-01-24 Synedgen, Inc. Zusammensetzungen und verfahren zur verwendung davon
JP2024530170A (ja) * 2021-08-02 2024-08-16 アルマタ・ファーマシューティカルズ・インコーポレーテッド 改善された抗微生物活性を有するバクテリオファージ

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4678750A (en) * 1984-10-18 1987-07-07 Microlife Technics, Inc. Method and compositions for use in the treatment of fireblight
US5032574A (en) 1988-05-26 1991-07-16 Invitron Corporation Novel antimicrobial peptide
US5242902A (en) * 1989-09-06 1993-09-07 The Regents Of The University Of California Defensin peptide compositions and methods for their use
JPH07507213A (ja) * 1992-05-22 1995-08-10 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア 消化器デフェンシン，そのｃＤＮＡ配列及び製造方法並びにその使用
WO1994019006A1 (fr) * 1993-02-24 1994-09-01 Gunze Limited Remede contre la fibrose kystique
US5459235A (en) 1993-03-19 1995-10-17 The Regents Of The University Of California Antimicrobial peptides antibodies and nucleic acid molecules from bovine neutrophils
US5550109A (en) 1994-05-24 1996-08-27 Magainin Pharmaceuticals Inc. Inducible defensin peptide from mammalian epithelia
JP2000508322A (ja) * 1996-04-15 2000-07-04 エヌワイエムオーエックス コーポレーション バクテリオファージを含有する組成物および感染症を治療するためのバクテリオファージの使用方法
US20020037260A1 (en) * 1997-10-16 2002-03-28 Budny John A. Compositions for treating biofilm
DE69838473T2 (de) * 1997-12-25 2008-01-17 Nihon Kohden Corp. Gerät zur Übertragung von biologischen Signalen
ATE305793T1 (de) 2000-07-25 2005-10-15 Us Gov Health & Human Serv Bakteriophage mit breitem wirtspektrum

Also Published As

Publication number Publication date
US20060140911A1 (en) 2006-06-29
US7758856B2 (en) 2010-07-20
GB0300597D0 (en) 2003-02-12
EP1587520B1 (de) 2009-08-12
EP1587520A1 (de) 2005-10-26
DE602004022506D1 (de) 2009-09-24
WO2004062677A9 (en) 2004-10-07
WO2004062677A1 (en) 2004-07-29

Similar Documents

Publication Publication Date Title
ATE439139T1 (de) Bakteriophage zur behandlung von bakteriellen biofilmen
EA200600280A1 (ru) Композиции на основе производных липопептидных антибиотиков и способы их применения
ATE534372T1 (de) Verfahren und zusammensetzungen zur behandlung und prävention von infektionen
ATE524195T1 (de) Monoklonale antikörper gegen das clfa-protein und verfahren zur verwendung bei der behandlung bzw. pr vention von infektionen
ATE513551T1 (de) Zusammensetzungen und verfahren zur wiederherstellung der bakterienflora
DE60113851D1 (de) Bakteriophage mit breitem wirtspektrum
ATE448775T1 (de) Rifalazil zur behandlung von infektionen mit clostridium difficile
EP1784171A4 (de) Zusammensetzungen zur topischen anwendung am ohr und verfahren zur topischen behandlung oder prävention von ohrentzündungen
ATE481134T1 (de) Zusammensetzungen und verwendung von tyrosinkinase-hemmern zur behandlung von pathogenen infektionen
NO20083245L (no) Sykliske antimikrobielle peptider
NO20080338L (no) Forbindelser for behandling av multilegemiddelresistente bakterielle infeksjoner
DK1663168T3 (da) Nikotinformuleringer og anvendelse deraf
NZ595252A (en) Biofilm treatment
UA88463C2 (ru) Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции
ATE427116T1 (de) Behandlung von bakteriellen infektionen
TW200734344A (en) Antibacterial agents
DE69835536D1 (de) Zusammensetzungen zur behandlung von staphylococcus aureus infektionen
DK1675603T3 (da) Anvendelse af probiotiske bakterier i behandling af infektion
MX2022006109A (es) Derivados 1-aminosulfonil-2-carboxipirrol como inhibidores de metalo-beta-lactamasa.
AR029544A1 (es) Composiciones y metodos para tratar infecciones bacterianas
DE602004028574D1 (de) Zusammensetzungen und verfahren zur behandlung des reizdarmsyndroms und von nichtulzeröser dyspepsie
WO2003061704A3 (en) Combination therapy for the treatment of bacterial infections
DE60142786D1 (de) Zusammensetzungen und methoden zur behandlung von candidosen
DE60331781D1 (de) Verwendung von synergistischen lytischen enzymen aus bakteriophagen zur vorbeugung und behandlung bakterieller infektionen
WO2019222502A8 (en) Endolysins active against bacillus bacteria, pharmaceutical compositions, and methods relating thereto

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties